Kevin P Bateman

Merck's perspective on the implementation of dried blood spot technology in clinical drug development - why, when and how.

Yang Xu, Eric J Woolf, Nancy Gb Agrawal, 2013, Bioanalysis.

IQ consortium perspective: complementary LBA and LC-MS in protein therapeutics bioanalysis and biotransformation assessment.

Jianing Zeng, Surinder Kaur, Kevin P Bateman, 2020, Bioanalysis.

Digitally Enabled, Patient‐Centric Clinical Trials: Shifting the Drug Development Paradigm

Bryan J Hansen, Kevin P Bateman, Marissa F Dockendorf, 2020, Clinical and translational science.

Standardized workflows for increasing efficiency and productivity in discovery stage bioanalysis.

Vincenzo Pucci, Kevin P Bateman, Lucinda Cohen, 2013, Bioanalysis.

Discovery stage pharmacokinetics using dried blood spots.

Kevin P Bateman, K. Bateman, Patrick Beaudette, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

MSE with mass defect filtering for in vitro and in vivo metabolite identification.

Mark Wrona, Kevin P Bateman, R. Oballa, 2007, Rapid communications in mass spectrometry : RCM.

Quantitation of a Therapeutic Antibody in Serum Using Intact Sequential Affinity Capture, Trypsin Digestion, and LC-MS/MS.

Kevin P Bateman, Daniel S Spellman, Wolfgang Seghezzi, 2018, Analytical chemistry.

Microdosing Cocktail Assay Development for Drug-Drug Interaction Studies.

Kevin P Bateman, Dina Goykhman, K. Bateman, 2018, Journal of pharmaceutical sciences.

'All-in-one' analysis for metabolite identification using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry with collision energy switching.

Mark Wrona, Desmond O'Connor, Kevin P Bateman, 2005, Rapid communications in mass spectrometry : RCM.

Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies.

Sean Yu, Kevin P Bateman, T. Baillie, 2008, Rapid communications in mass spectrometry : RCM.